Plain-English translation of NCT06891365 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it can safely treat fatty liver disease and liver inflammation. The medication is given as an injection under the skin once a month for three months. Researchers want to understand how safe the treatment is, how well people tolerate it, and how the body processes it.
Fatty liver disease is becoming increasingly common, and currently there are no approved medications to treat it. This study aims to find out whether this new treatment could offer hope to people living with this condition.
You likely qualify if…
You likely don't qualify if…
You would receive a subcutaneous injection (a shot under your skin) once a month for three months, either the test medication or a placebo (dummy treatment). You'll have several visits over about 58 weeks for blood tests, physical exams, and imaging scans to monitor your liver health. Some participants may also have a liver biopsy (a small tissue sample taken from the liver) to help doctors understand how well the treatment is working.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United Kingdom
Sponsor
Novo Nordisk A/S
Enrollment target
~48 participants
Started
March 2025
Primary completion
October 2027
Age range
18 Years – 64 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novo Nordisk
Novo Nordisk A/S
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.